Clinical Profile, Management Strategy, and Outcomes of Patients with Prosthetic Valve Thrombosis

Overview

Journal Glob Cardiol Sci Pract

Specialty Cardiology & Vascular Diseases

Date 2025 Feb 11

PMID 39931452

Authors

Waqar Khan

Arsalan Younus

Muhammad Imran Ansari

Jehangir Ali Shah

Mariam Naz

Raheela Khawaja

Aamir Khowaja

Taimur Asif Ali

Munawar Khursheed

Tahir Saghir

Affiliations

Soon will be listed here.

Abstract

Prosthetic valve thrombosis (PVT) is a severe complication following prosthetic heart valve replacement, particularly in inadequately anticoagulated patients. Primary treatment options include intensive anticoagulation therapy, thrombolytic treatment (TT), and emergency surgery. This study aims to evaluate the clinical profile, management strategies, and short-term outcomes of patients with PVT. Consecutive patients with PVT presenting to the emergency department of a tertiary care cardiac center were included in this study. Responses to treatment, hospital outcomes, and 30-day outcomes post-treatment were observed. A total of 75 patients were analyzed, with a male predominance (50.7%) and a mean age of 39.5 ± 12.3 years. Bi-leaflet prosthetic valves were most common (96.0%), 54 (72.0%) had prosthetic mitral valve and 10 (13.3%) had prosthetic both mitral and aortic valves. Atrial fibrillation was present in 25.3% of cases. Treatment predominantly involved streptokinase (74.7%), followed by heparin (37.3%) and VKA (9.3%). Clinical success was achieved in 84.0% of cases, while 12.0% experienced clinical failure, including severe complications such as irreversible neurologic damage (1.3%) and bleeding (2.8%). The 30-day mortality rate was 12.0%, with recurring PVT and bleeding/embolic complications each in 1.5% of cases. Treatment of PVT with streptokinase, heparin, and VKA demonstrates efficacy, with a substantial proportion of patients achieving complete clinical success. However, the study highlights concerning outcomes, including clinical failure and severe complications. These findings underscore the importance of carefully balancing thrombolytic and anticoagulant therapies to mitigate potential adverse events.

References

Aluru J, Barsouk A, Saginala K, Rawla P, Barsouk A . Valvular Heart Disease Epidemiology. Med Sci (Basel). 2022; 10(2). PMC: 9228968. DOI: 10.3390/medsci10020032. View

Mahindru S, Pande S, Malhotra P, Thukral A, Kotwal A, Gupta R . Mechanical prosthetic valve thrombosis in current era: 5-year follow-up. Indian J Thorac Cardiovasc Surg. 2021; 37(2):140-146. PMC: 7876196. DOI: 10.1007/s12055-020-01041-9. View

Sr K, G B, Jain S, Moorthy N, Manjunath S, Christopher R . Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes. Medicine (Baltimore). 2019; 98(6):e14365. PMC: 6380714. DOI: 10.1097/MD.0000000000014365. View

Roudaut R, Lafitte S, Roudaut M, Courtault C, Perron J, Jais C . Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. J Am Coll Cardiol. 2003; 41(4):653-8. DOI: 10.1016/s0735-1097(02)02872-3. View

Caceres-Loriga F, Perez-Lopez H, Morlans-Hernandez K, Facundo-Sanchez H, Santos-Gracia J, Valiente-Mustelier J . Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis. 2006; 21(2):185-90. DOI: 10.1007/s11239-006-4969-y. View

Otto C, Nishimura R, Bonow R, Carabello B, Erwin 3rd J, Gentile F . 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020; 77(4):450-500. DOI: 10.1016/j.jacc.2020.11.035. View

Yaminisharif A, Alemzadeh-Ansari M, Ahmadi S . Prosthetic tricuspid valve thrombosis: three case reports and literature review. J Tehran Heart Cent. 2013; 7(4):147-55. PMC: 3537206. View

Kathirvel D, Justin Paul G, Prathap Kumar G, Palanisamy G, Gnanavelu G, Ravishankar G . Tenecteplase versus streptokinase thrombolytic therapy in patients with mitral prosthetic valve thrombosis. Indian Heart J. 2018; 70(4):506-510. PMC: 6116712. DOI: 10.1016/j.ihj.2017.10.014. View

Kiran G, Chandrasekhar P, Mohammad Ali S . Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase. Indian Heart J. 2021; 73(3):365-368. PMC: 8322749. DOI: 10.1016/j.ihj.2021.02.005. View

10.

Santangelo G, Bursi F, Faggiano A, Moscardelli S, Simeoli P, Guazzi M . The Global Burden of Valvular Heart Disease: From Clinical Epidemiology to Management. J Clin Med. 2023; 12(6). PMC: 10054046. DOI: 10.3390/jcm12062178. View

11.

Lim W, Lloyd G, Bhattacharyya S . Mechanical and surgical bioprosthetic valve thrombosis. Heart. 2017; 103(24):1934-1941. DOI: 10.1136/heartjnl-2017-311856. View

12.

Noohi Bezanjani F, Gohari S, Bassiri H, Ahangar H, Reshadmanesh T . Risk Factors Associated with Heart Valve Thrombosis in Patients with Prosthetic Heart Valve Dysfunction. Arch Iran Med. 2020; 23(9):600-604. DOI: 10.34172/aim.2020.70. View

13.

Gunduz S, Ozkan M, Yesin M, Kalcik M, Gursoy M, Karakoyun S . Prolonged Infusions of Low-Dose Thrombolytics in Elderly Patients With Prosthetic Heart Valve Thrombosis. Clin Appl Thromb Hemost. 2015; 23(3):241-247. DOI: 10.1177/1076029615609698. View

14.

Milne O, Barthwal R, Agahari I, Ilton M, Kangaharan N . Management and Outcomes of Prosthetic Valve Thrombosis. An Australian Case Series From the Northern Territory. Heart Lung Circ. 2019; 29(3):469-474. DOI: 10.1016/j.hlc.2019.07.005. View

15.

Keuleers S, Herijgers P, Herregods M, Budts W, Dubois C, Meuris B . Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol. 2011; 107(2):275-9. DOI: 10.1016/j.amjcard.2010.09.013. View

16.

Yi B, Zeng W, Lv L, Hua P . Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories. Aging (Albany NY). 2021; 13(9):12710-12732. PMC: 8148466. DOI: 10.18632/aging.202942. View

17.

Zheng X, Guan Q, Lin X . Changing trends of the disease burden of non-rheumatic valvular heart disease in China from 1990 to 2019 and its predictions: Findings from global burden of disease study. Front Cardiovasc Med. 2023; 9:912661. PMC: 9897059. DOI: 10.3389/fcvm.2022.912661. View

18.

Caceres-Loriga F, Morais H . Thrombotic obstruction in left-side prosthetic valves: Role of thrombolytic therapy. Indian Heart J. 2015; 67 Suppl 2:S10-2. PMC: 4688444. DOI: 10.1016/j.ihj.2015.08.019. View

19.

Raman K, Mohanraj A, Palanisamy V, Ganesh J, Rawal S, Kurian V . Thrombolysis and surgery for mitral prosthetic valve thrombosis: 11-year outcomes. Asian Cardiovasc Thorac Ann. 2019; 27(8):633-640. DOI: 10.1177/0218492319878015. View

20.

Nishimura R, Otto C, Bonow R, Carabello B, Erwin 3rd J, Fleisher L . 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135(25):e1159-e1195. DOI: 10.1161/CIR.0000000000000503. View